LIGAND PHARMACEUTICALS INCORPORATED Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.44 million for the 12-month period ending 2010-12-31, per its 10-K filed 2013-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2013-03-14
- LIGAND PHARMACEUTICALS INCORPORATED effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2010 was $1.44M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2010-12-31 | $1.44M 10-K · filed 2013-03-14 |